NEW YORK (GenomeWeb) – The China Food and Drug Administration has approved next-generation sequencing-based products developed by BGI.

According to CFDA, it has approved BGISEQ-1000, BGISEQ-100, and diagnostic kits for fetal chromosomal aneuploidy that screen for trisomy 21, 18, and 13. The CFDA said the assays use semiconductor sequencing and joint probe anchor sequencing and will screen cell-free DNA in maternal plasma at 12 weeks or later gestation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.